News

Captor Therapeutics has applied for approval to conduct a Phase 1 clinical trial in Patients with Hepatocellular Carcinoma

Captor Therapeutics has signed an agreement for the implementation and funding of Stage II of the CT-01 Project

Captor Therapeutics signed the agreement for II phase implementation and financing for Project CT-03

Captor Therapeutics has published financial report for Q1-Q3 2023.

Captor Therapeutics has submitted phasing applications to NCBiR for projects CT-01 and CT-03

Captor Therapeutics has selected ICON as the CRO company to conduct the first phase of clinical trials under the CT-01 project

Captor Therapeutics will raise PLN 40 million from share issue for implementation of strategic goals

Captor Therapeutics appoints Wedbush as its exclusive strategic financial advisor and establishes relationship with MSQ Ventures in China